KSKira J. Stanzick

Kira J. Stanzick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kira J. Stanzick has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Adriana M. Hung

    Department of Veteran’s Affairs, Tennessee Valley Healthcare System (626)/Vanderbilt University, Nashville, USA

    1 shared publication
  • Andre Gessner

    Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany

    1 shared publication
  • Anna Köttgen

    Institute of Genetic Epidemiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    1 shared publication
  • Bjørn Olav Åsvold

    HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway

    1 shared publication
  • Brett R. Vanderweff

    Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, USA

    1 shared publication
  • Bryce X. Rowan

    Department of Biostatistics, Vanderbilt University Medical Center, Nashville, USA

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Discovery and prioritization of variants and genes for kidney function in >1.2 million individuals

    by Kira J. Stanzick, Yong Li, Pascal Schlosser, Mathias Gorski, Matthias Wuttke, Laurent F. Thomas, Humaira Rasheed, Bryce X. Rowan, Sarah E. Graham, Brett R. Vanderweff, et al.

    Genes underneath signals from genome-wide association studies (GWAS) for kidney function are promising targets for functional studies, but prioritizing variants and genes is challenging. By GWAS meta-analysis for creatinine-based estimated glomerular filtration rate (eGFR) from the Chronic Kidney Disease Genetics Consortium and UK Biobank (n = 1,201,909), we expand the number of eGFRcrea loci (424 loci, 201 novel; 9.8% eGFRcrea variance explained by 634 independent signal variants). Our increased sample size in fine-mapping (n = 1,004,040, European) more than doubles the number of signals with resolved fine-mapping (99% credible sets down to 1 variant for 44 signals, ≤5 variants for 138 signals). Cystatin-based eGFR and/or blood urea nitrogen association support 348 loci (n = 460,826 and 852,678, respectively). Our customizable tool for Gene PrioritiSation reveals 23 compelling genes including mechanistic insights and enables navigation through genes and variants likely relevant for kidney function in human to help select targets for experimental follow-up.